- 21Shares has filed a new spot Injective (INJ) ETF application with the U.S. Securities and Exchange Commission.
- The issuer submitted the application on October 20, 2025, making Injective one of the altcoins with multiple ETF filings pending before the SEC.
- INJ traded around $8.75 as the cryptocurrency appeared to bounce off recent lows amid ETF-driven bullish sentiment.
21Shares, a prominent issuer of cryptocurrency exchange-traded products, has submitted a new filing for a spot exchange-traded fund (ETF) with the U.S. Securities and Exchange Commission.
The native token of Injective, INJ, saw a modest uptick following the news, with buyers holding above the $8.00 level.
21Shares files for new spot Injective ETF
The official Injective account on X shared the news of 21Shares’ INJ ETF filing with the SEC on Monday.
According to the filing, the proposed 21Shares Injective ETF aims to provide investors with direct exposure to INJ.
Like other proposed listings and following the successful launches of spot Bitcoin and Ethereum ETFs, the 21Shares Injective ETF would be an exchange-traded fund that holds physical INJ tokens in cold storage.
“This is a major signal of growing institutional interest, making $INJ one of the few digital assets with multiple ETF products in progress,” the Injective team posted on X.
Injective ranks among the top 100 cryptocurrencies, and its growth in the industry has coincided with rising interest in sectors such as decentralized finance (DeFi) and real-world assets.
Recently, the layer-1 project held the inaugural Injective Council meeting.
Platform adoption and development have received meaningful support from industry leaders advocating for core roadmap priorities, including a native Ethereum Virtual Machine, a digital-asset treasury, the INJ ETF, and pre-IPO market access.
Key partners include Google Cloud, T-Mobile, Deutsche Telekom, YZi Labs, Galaxy Digital, and BitGo.
Earlier, Canary Capital had also filed an INJ ETF application in July.
Injective is a high-performance Layer 1 blockchain engineered for decentralized financial services. The platform can process more than 25,000 transactions per second and uses its native token, INJ, to secure the network via a delegated proof-of-stake (DPoS) consensus mechanism.
The blockchain addresses infrastructure challenges such as fragmented liquidity and slow transaction finality by integrating exchange primitives with CosmWasm-based composability, while Comet BFT (formerly Tendermint BFT) ensures fast finality.
INJ price outlook as ETF approval buzz lifts sentiment
As noted, INJ traded near $8.75 amid broader crypto market volatility.
Although the token did not spike sharply on the ETF news, market enthusiasm has risen.
Optimism largely stems from expectations that the SEC may approve multiple crypto ETFs, which could remove downward pressure and open the door for bulls to regain control.
Injective’s price has corrected significantly from its December 2024 peak near $35 and remains far below its all-time high of $52.75 reached in March 2024.
Still, bulls have aimed to defend the $8.00 level after INJ briefly fell to around $7.80 following a dip on October 17, 2025.
Previously, INJ showed resilience by bouncing from an April low of $6.90.
Beyond ETF-driven sentiment, other bullish factors include treasury moves such as a $100 million transfer by Pineapple Financial, which has supported buying pressure.
Overall, the 21Shares filing adds to a growing list of institutional interest signals for Injective, and market participants will be watching SEC developments closely as they assess INJ’s medium-term prospects.